[Clinical evaluation of sulbactam/ampicillin in the pediatric infections].

Abstract

Sulbactam/ampicillin (SBT/ABPC) was administered to 33 pediatric inpatients with 34 bacterial infections. Clinical efficacies were judged to be good in 33 cases (97.1%) out of 34 which included 13 cases of 14 with infections caused by beta-lactamase-producing strains of organisms, and successfully cured by this drug. There were no particular side effects to comment except some cases of diarrhea and loose stool. These results indicated that SBT/ABPC would be useful in the treatment of pediatric infections as a first choice of drug. Serum half-lives of ABPC and SBT were 0.79 hour and 1.02 hours, respectively, hence, q.i.d. dosage regimen would be appropriate.

• Authors: H Meguro, O Arimasu, H Shiraishi, K Sugamata, F Hiruma, T Abe, R Fujii, J Mashiko, Y Nagao, Y Okamoto
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 42 Issue 3 Pg. 612-22 (Mar 1989) ISSN: 0368-2781 [Print] Japan
• PMID: 2746845 (Publication Type: English Abstract, Journal Article)

Chemical References

• Ampicillin
• Sulbactam

Topics

• Age Factors
• Ampicillin (pharmacokinetics, therapeutic use)
• Bacterial Infections (drug therapy, metabolism)
• Child
• Child, Preschool
• Drug Therapy, Combination (pharmacokinetics, therapeutic use)
• Female
• Half-Life
• Humans
• Infant
• Injections, Intravenous
• Male
• Respiratory Tract Infections (drug therapy, metabolism)
• Sulbactam (pharmacokinetics, therapeutic use)